SGMT
NASDAQ · Biotechnology
Sagimet Biosciences Inc-A
$7.60
-0.05 (-0.65%)
Open$7.63
Previous Close$7.65
Day High$7.73
Day Low$7.33
52W High$11.41
52W Low$3.08
Volume—
Avg Volume1.03M
Market Cap450.93M
P/E Ratio—
EPS$-1.79
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
-60.5% upside
Current
$7.60
$7.60
Target
$3.00
$3.00
$2.20
$3.00 avg
$3.42
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 28.61M | 29.26M | 29.39M |
| Net Income | 3.39M | 4.16M | 4.24M |
| Profit Margin | 11.8% | 14.2% | 14.4% |
| EBITDA | 5.59M | 5.60M | 5.84M |
| Free Cash Flow | 4.74M | 2.94M | 4.50M |
| Rev Growth | +24.7% | +14.4% | -5.6% |
| Debt/Equity | 0.41 | 0.48 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |